drugset / Trial / NCT04248712

Antihistamines in Eosinophilic Esophagitis

NCT04248712

Phase 2 Terminated 1 enrolled Mayo Clinic
RandomizedParallel-groupSingle-blindTreatment

Summary

Researchers are assessing the safety and effectiveness of antihistamines in the treatment of eosinophilic esophagitis.

Timeline

Start
2020-07-10
Primary completion
2021-12-31
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Famotidine Other / unclassified 40 mg Oral
Subject Loratadine Small molecule 10 mg Oral